Golden Diagnostics

Raghu Kannan

“THE NEW GOLD STANDARD IN

COMPANION DIAGNOSTICS”

Introductory Slide

Current methods of detectionIHC: Dako –in accuratePCR –amplifies all genes FISH –works well; however, microscopic visualization of tumor regions is difficult

First Target: NSCLCQuantify proteinsQuantify genesEffective treatment plan

Detects and quantifies proteins in tumor tissue.

Unmet Market or Clinical Need

Lung Cancer (2014) Incidence 221,200; Mortality: 158,040

The heterogeneity of NSCLC makes effective treatment dependent on knowledge of the patient’s tumor biomarkers (and mutations)

Cost of targeted therapy: $100,000

A diagnostic test platform that enables identification and quantitation of all types of tumor biomarkers (and mutation) is needed

Value Proposition

Platform Technology: Gold nanorod mediated targeted histochemistry” (GNR-HC).

Can identify and precisely quantify biomarkers in human tissues Highly sensitive.Can detect and quantify all classes of tumor biomarkers (e.g., proteins, mutations, gene fusion, copy number variants)

Business Model / Customer Development / Delivering Your SolutionBusiness model.

Diagnostic kit supplied to pathology laboratories.Oncologists –order to provide effective treatment plan.Pharmaceutical companies use as companion diagnostics.

Market strategyStart up: Golden DiagnosticsIDE; PMA pathway$250K for Pre-IDE phase$1-$1.5 million for IDE and PMA approval

Intellectual Property / Proprietary Technology

Building Management Teams and Advisory Board / Network DevelopmentRaghu Kannan –Business

development and nanotechnologyCo-founder of three start-ups; raised more than $3 million in funding.

Gerald Arthur –Board Certified PathologistPartners and potential partners

Regulatory specialists –Dr. Anandhi UpendranIndustry contacts –Eli Lilly for providing human samples and expertise

Financial Projections and Milestones